Marc Goodman
Stock Analyst
(3.63)
# 862
Out of 4,648 analysts
99
Total ratings
54.55%
Success rate
21.55%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $50.04 | +19.90% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $28.43 | +12.56% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $5.70 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $69.71 | -64.14% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $27.21 | +83.76% | 1 | Jan 30, 2023 | |
| RLMD Relmada Therapeutics | Maintains: Outperform | $42 → $10 | $3.42 | +192.40% | 2 | Jan 23, 2023 | |
| MRNS Marinus Pharmaceuticals | Maintains: Outperform | $27 → $23 | $0.33 | +6,815.21% | 4 | Jan 23, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $16.42 | +21.80% | 3 | Jan 19, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $65 → $85 | $87.25 | -2.58% | 6 | Nov 29, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $120.53 | -4.59% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $173.52 | +78.65% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $14.86 | -19.25% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $41.71 | +10.29% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $14.62 | +43.64% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $109.41 | +91.94% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $5.81 | +588.47% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.94 | +240.14% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $26.59 | +1.54% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.21 | +493.82% | 1 | Apr 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $70 | $86.17 | -18.77% | 3 | Apr 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.18 | +189.58% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $383.90 | -29.67% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $200.47 | -52.11% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $55.45 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $101.87 | -34.23% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $25.41 | +285.67% | 7 | Oct 5, 2017 |
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $50.04
Upside: +19.90%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $28.43
Upside: +12.56%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $5.70
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $69.71
Upside: -64.14%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $27.21
Upside: +83.76%
Relmada Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $42 → $10
Current: $3.42
Upside: +192.40%
Marinus Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $27 → $23
Current: $0.33
Upside: +6,815.21%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $16.42
Upside: +21.80%
Axsome Therapeutics
Nov 29, 2022
Maintains: Outperform
Price Target: $65 → $85
Current: $87.25
Upside: -2.58%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $120.53
Upside: -4.59%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $173.52
Upside: +78.65%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $14.86
Upside: -19.25%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $41.71
Upside: +10.29%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $14.62
Upside: +43.64%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $109.41
Upside: +91.94%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $5.81
Upside: +588.47%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.94
Upside: +240.14%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $26.59
Upside: +1.54%
Apr 26, 2022
Initiates: Outperform
Price Target: $25
Current: $4.21
Upside: +493.82%
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $86.17
Upside: -18.77%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.18
Upside: +189.58%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $383.90
Upside: -29.67%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $200.47
Upside: -52.11%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $55.45
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $101.87
Upside: -34.23%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $25.41
Upside: +285.67%